Study on Continuing Futibatinib Treatment for Patients from Previous Trials
Sponsor: Taiho Oncology, Inc.
ClinicalTrials ID:NCT06506955
This study allows patients who were part of earlier trials with the drug futibatinib, either alone or in combination with other treatments, to continue their therapy if they are benefiting from it without any significant risks.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
This study is designed for patients who have been participating in previous trials involving the drug futibatinib, either as a standalone treatment or combined with other therapies. The aim is to allow these patients to continue receiving futibatinib if they are experiencing positive effects and no major side effects, as determined by their doctor.
Description
This study, known as TAS-120-404, is open to patients who have been part of earlier trials with futibatinib, a medication used either on its own or with other treatments. If patients are still benefiting from futibatinib and not experiencing any significant risks, they can continue their treatment in this study. The decision to continue is based on the doctor's assessment, and patients must not have met any criteria that would have required them to stop treatment in the previous study.
Eligibility Criteria
Inclusion Criteria
- Must provide written consent to participate.
- Currently receiving futibatinib, either alone or with other treatments, and benefiting from it without significant risks, as judged by the doctor.
- Women who can become pregnant must have a negative pregnancy test before starting the study and agree to use effective birth control during the study and for a specified time after.
- Must be able to take medications by mouth (cannot use a feeding tube).
Exclusion Criteria
- Have met any criteria that required stopping treatment in the previous futibatinib study.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| University of California, San Francisco (UCSF) | 94143 | San Francisco | California |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.